MANAGING CHRONIC WOUNDS IN CLINICAL PRACTICE(P3)
60 min
Saturday, May 03, 2025
10:30 AM - 11:30 AM
ROOM: Fort Worth 6
MODERATORS: MONIKA ANNA NIEWCZAS, PHD; BRIAN SCHMIDT, PHD
P3.01. Cellular vs. Acellular Matrix Products For Diabetic Foot Ulcer Treatment: A Randomized Clinical Trial
Harrison J. Shawa1; Ramanjot Kaur1; Catherine Tchanque-Fossuo1; Hadar Lev-Tov1,2; Kaitlyn West1; Pallas Lim1; Nuen Yang1; Mirabel Dafinone1; Rawlings E. Lyle1; Chin Chang1; David Rocke1; Sara Dahle1; Rivkah Isseroff1
1Dermatology, Veterans Affair and UC Davis, Mather, CA, United States; 2Dermatology, University of Miami, Miami, FL, United States
P3.02. Development of a Porcine Hard-To-Heal Wound Model And Evaluation Of A Bromelain-Based Enzymatic Debriding Agent
Yaron Shoam1; Adam J. Singer2
1Plastic and Reconstructive Surgery, Soroka Medical Center, Ben-Gurion University, Beer-Sheba, Israel; 2Emergency Medicine, Renaissance School of Medicine at Stony Brook, University, Stony Brook, NY, United States
P3.03. Bromelain Based Debridement - Molecular Mode Of Action
Dafna Geblinger; Eilon Asculai
MediWound Ltd, Yavne, Israel
P3.04. Photographic Guidance For Pyoderma Gangrenosum: Optimizing Photography In The Era Of Decentralized Clinical Trials
Morgan Vague1; Martha Oberg2; Emile Latour1; Angelo Marzano3; Willy Huang5; Robert McLafferty6; Robert Kelly7; Elizabeth White-Chu6; Arash Mostaghimi4; Alex Ortega-Loayza1
1Dermatology, Oregon Health and Science University, Portland, OR 97239, OR, United States; 2Washington State University College of Medicine, Spokane, WA, United States; 3Derma, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; 4Dermatology, Harvard Medical School, Boston, MA, United States; 5Dermatology, Duke University School of Medicine, Durham, NC, United States; 6Oregon Health and Science University, Portland, OR, United States; 7Dermatology, St. Vincent’s Hospital, Melbourne, VIC, Australia
P3.05. Intravenous Fibonectin (FN)-Derived cNP8 Peptide Phase 1 Study
Susan Szambelan2; Richard A. Clark1
1NeoMatrix Therapeutics, East Setauket, NY, United States; 2Clinical Research, NeoMatrix Therapeutics, Inc., Stony Brook, NY, United States
P3.06. Bethlem Myopathy: A Unique Presentation With Diffuse Spontaneous Keloids
Anuj Budhiraja1; Harrsion Shawa2; Alisha Mehta1; Mirabel Dafinone3; Catherine Tchanque-Fossuo4; Maija Kiuru4; Sara Dahle5; Rivkah Isseroff4
1California Northstate University, Elk Grove, CA, United States; 2Dermatology, Washington University in St. Louis, St Louis, MO, United States; 3University of Nevada Reno, Reno, NV, United States; Dermatology, University of California, Davis, Sacramento, CA, United States; 5Podiatry, VA Northern California Health Care System, Mather, CA, United States
MODERATORS: MONIKA ANNA NIEWCZAS, PHD; BRIAN SCHMIDT, PHD
P3.01. Cellular vs. Acellular Matrix Products For Diabetic Foot Ulcer Treatment: A Randomized Clinical Trial
Harrison J. Shawa1; Ramanjot Kaur1; Catherine Tchanque-Fossuo1; Hadar Lev-Tov1,2; Kaitlyn West1; Pallas Lim1; Nuen Yang1; Mirabel Dafinone1; Rawlings E. Lyle1; Chin Chang1; David Rocke1; Sara Dahle1; Rivkah Isseroff1
1Dermatology, Veterans Affair and UC Davis, Mather, CA, United States; 2Dermatology, University of Miami, Miami, FL, United States
P3.02. Development of a Porcine Hard-To-Heal Wound Model And Evaluation Of A Bromelain-Based Enzymatic Debriding Agent
Yaron Shoam1; Adam J. Singer2
1Plastic and Reconstructive Surgery, Soroka Medical Center, Ben-Gurion University, Beer-Sheba, Israel; 2Emergency Medicine, Renaissance School of Medicine at Stony Brook, University, Stony Brook, NY, United States
P3.03. Bromelain Based Debridement - Molecular Mode Of Action
Dafna Geblinger; Eilon Asculai
MediWound Ltd, Yavne, Israel
P3.04. Photographic Guidance For Pyoderma Gangrenosum: Optimizing Photography In The Era Of Decentralized Clinical Trials
Morgan Vague1; Martha Oberg2; Emile Latour1; Angelo Marzano3; Willy Huang5; Robert McLafferty6; Robert Kelly7; Elizabeth White-Chu6; Arash Mostaghimi4; Alex Ortega-Loayza1
1Dermatology, Oregon Health and Science University, Portland, OR 97239, OR, United States; 2Washington State University College of Medicine, Spokane, WA, United States; 3Derma, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; 4Dermatology, Harvard Medical School, Boston, MA, United States; 5Dermatology, Duke University School of Medicine, Durham, NC, United States; 6Oregon Health and Science University, Portland, OR, United States; 7Dermatology, St. Vincent’s Hospital, Melbourne, VIC, Australia
P3.05. Intravenous Fibonectin (FN)-Derived cNP8 Peptide Phase 1 Study
Susan Szambelan2; Richard A. Clark1
1NeoMatrix Therapeutics, East Setauket, NY, United States; 2Clinical Research, NeoMatrix Therapeutics, Inc., Stony Brook, NY, United States
P3.06. Bethlem Myopathy: A Unique Presentation With Diffuse Spontaneous Keloids
Anuj Budhiraja1; Harrsion Shawa2; Alisha Mehta1; Mirabel Dafinone3; Catherine Tchanque-Fossuo4; Maija Kiuru4; Sara Dahle5; Rivkah Isseroff4
1California Northstate University, Elk Grove, CA, United States; 2Dermatology, Washington University in St. Louis, St Louis, MO, United States; 3University of Nevada Reno, Reno, NV, United States; Dermatology, University of California, Davis, Sacramento, CA, United States; 5Podiatry, VA Northern California Health Care System, Mather, CA, United States
-
Room
- Fort Worth 6